Choosing a Long-Term HAE Prophylaxis Regimen When Cost Decides What Evidence Alone Would Not
The strongest trial data belongs to the drug her insurance won't cover without a fight she doesn't have the coverage to win. What she actually starts on turns out to be decided by access, not efficacy.
She is finishing her nursing degree with clinical rotations that don't pause for anything, three hereditary angioedema attacks a month over the last four months making an already demanding schedule harder to hold together. She and her partner have also told the team plainly that they're planning to start a family within the next two or three years — a detail that turns out to matter as much to today's decision as her attack frequency does.
Lanadelumab carries the strongest randomized trial evidence among current long-term prophylaxis options for reducing attack frequency, but her insurance plan places it behind a prior-authorization and appeal process estimated at three to four weeks — not a denial, but a real delay for someone averaging three attacks a month. Berotralstat, an oral option with solid but smaller Phase 3 evidence behind it in APeX-2, sits on her formulary without that barrier. Danazol, the older standard, remains cheaper still but carries androgenic and teratogenic risks that her own stated plan to have children within a few years puts well outside acceptable territory regardless of the other two options' comparative merits.
She was diagnosed with HAE Type I only four months ago, after a peripheral swelling episode during a clinical rotation prompted a workup her preceptor insisted on rather than letting her attribute it, as she initially did, to a bee sting she couldn't actually recall receiving. She has no other chronic medical conditions, does not smoke, and has tolerated on-demand icatibant well for the two breakthrough attacks she's had since diagnosis, giving the team a real, if brief, baseline for how she responds to at least one of the drugs already in her regimen.
What the trial data says against what the formulary allows
The HELP trial gives lanadelumab the strongest attack-frequency reduction of anything we'd be choosing between. Absent a specific reason not to use it, I'd want to start there.
I don't dispute the trial comparison, but a three-to-four-week prior authorization process is a real cost when she's averaging three attacks a month right now — that appeal window is three more attacks, on a rotation schedule that doesn't pause for them. Berotralstat's APeX-2 data is genuinely solid, even if the effect size is smaller than HELP's, and it's available to start today with no appeal process standing in the way.
This isn't a claim that berotralstat is the better drug on paper — it's that the better drug on paper isn't actually available to her for a month, and a month of three more attacks is not a cost-free way to wait for the stronger option.
I want to close off a third option before we go further — danazol is cheaper and has a long track record, but given that she and her partner are planning to have children in the next few years, its androgenic effects and teratogenicity make it inappropriate for her regardless of how the lanadelumab-versus-berotralstat question gets resolved. That's not a close call given what she's told us about her plans.
Agreed: start berotralstat today given immediate formulary access and her current attack frequency, while filing the lanadelumab prior-authorization appeal in parallel rather than waiting to see how berotralstat performs first.
Danazol was closed off explicitly and by name, not merely left unmentioned, given her stated reproductive plans — a decision none of the three voices treated as needing further debate once raised.